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Abstract
Tuberculosis (TB) remains a leading cause of mortality worldwide. With the emergence of multidrug resistant TB, extensively
drug resistant TB and HIV-associated TB it is imperative that new drug targets be identified. The potential of Mycobacterium
tuberculosis inosine monophosphate dehydrogenase (IMPDH) as a novel drug target was explored in the present study.
IMPDH exclusively catalyzes the conversion of inosine monophosphate (IMP) to xanthosine monophosphate (XMP) in the
presence of the cofactor nicotinamide adenine dinucleotide (NAD
+). Although the enzyme is a dehydrogenase, the enzyme
does not catalyze the reverse reaction i.e. the conversion of XMP to IMP. Unlike other bacteria, M. tuberculosis harbors three
IMPDH-like genes, designated as Mt-guaB1, Mt-guaB2 and Mt-guaB3 respectively. Of the three putative IMPDH’s, we
previously confirmed that Mt-GuaB2 was the only functional ortholog by characterizing the enzyme kinetically. Using an in
silico approach based on designed scaffolds, a series of novel classes of inhibitors was identified. The inhibitors possess
good activity against M. tuberculosis with MIC values in the range of 0.4 to 11.4 mgm L
21. Among the identified ligands, two
inhibitors have nanomolar Kis against the Mt-GuaB2 enzyme.
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Introduction
Tuberculosis (TB) is still a worldwide problem as the number of
new cases continues to grow, approaching 9.8 million in 2010 and
resulting in approximately 1.68 million deaths in 2009 [1,2].
Human immunodeficiency virus (HIV) co-infection is a crucial
factor in the rise in the number of TB cases and the development
of active tuberculosis [1,3]. In addition, multidrug resistant and
extensively drug resistant strains continue to evolve, making
current treatments ineffective [4,5]. To counter the drug resistance
problem there is a crucial need to identify new drug targets.
Inosine monophosphate (IMP) is obtained in mycobacteria by the
de novo purine nucleotide biosynthesis pathway wherein the purine
ring is assembled in a stepwise manner starting from phosphor-
ibosyl pyrophosphate through eleven distinct enzymatic steps [6].
IMP is a common precursor for both adenine and guanine
nucleotide synthesis [7]. The first of the two steps towards guanine
nucleotide biosynthesis is catalysed by inosine monophosphate
dehydrogenase (IMPDH) which converts IMP to xanthosine
monophosphate (XMP) with the concomitant conversion of
NAD
+ to NADH. The IMPDH reaction equilibrium strongly
favors the forward reaction and maintains the guanine nucleotide
pool [8]. In M. tuberculosis Mt-GuaB2 is solely responsible for this
essential function, since out of the three genes that encode IMPDH
[9] Mt-GuaB2 is the only functional ortholog [10].
IMPDH is considered an attractive target for immunosuppres-
sive, cancer, antiviral, and antimicrobial therapy [11]. A genome
wide transposon mutagenesis study indicated that M. tuberculosis
requires Mt-GuaB2 for its survival [12,13]. IMPDH inhibitors
cause a reduction of guanine nucleotide levels and increase
adenine nucleotides in vivo, and subsequently, DNA and RNA
synthesis is interrupted resulting in cytotoxicity [11,14,15].
Depending on the mode of enzyme binding, IMPDH inhibitors
are classified into three types: type I inhibitors are IMP/XMP
analogues, type II are NAD
+/NADH analogues and type III are
multisubstrate inhibitors [16]. The first known IMPDH inhibitor
was the mold metabolite mycophenolic acid (MPA) which is a type
II inhibitor. MPA requires no metabolic activation and binds at
the NAD
+ site [16]. Other type II inhibitors like tiazofurin and
selenazofurin must first be metabolically activated to adenine
dinucleotides, thiazole-4-carboxamide adenine dinucleotide
(TAD) and selenazole-4-carboxamide adenine dinucleotide
(SAD) in vivo to become inhibitors [16]. The nucleoside analogue
tiazofurin and its derivatives are uncompetitive inhibitors
[6,17,18]. Typical type I inhibitors such as ribavirin and
mizoribine bind at the substrate site [19].
MPA inhibits by trapping enzyme-XMP* (E-XMP*) as a
covalent intermediate, and the pattern of inhibition is uncompet-
itive with respect to both the substrates IMP and NAD
+ due to the
strong preference for E-XMP* [11,14]. MPA and mizoribine are
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antiviral chemotherapy [6,20]. Mizoribine (MZP), an IMP
analogue, is a potent inhibitor of microbial enzymes [21]. The
phenyloxazole urea scaffolds were discovered in a structure-based
drug design effort at Vertex Pharmaceuticals. Like MPA, these
compounds trap the covalent intermediate E-XMP* complex.
Imidazo[4,5-e][1,4]diazapine nucleotide is a potent inhibitor of
Escherichia coli IMPDH [22]. Although halicyclamine was originally
identified as a human IMPDH type II inhibitor, it was recently
found that the antitubercular activity of halicyclamine was not due
to inhibition of IMPDH [14,23]. The first potent inhibitors of Mt-
GuaB2 reported were the triazole linked mycophenolic adenine
dinucleotides which showed uncompetitive inhibition with both
NAD
+ and IMP [24]. Recently, several analogues in the diphenyl
urea (DPU) class of Mt-GuaB2 inhibitors were selected based on
their potent antitubercular activity and informatics analysis [10].
Among the characterized bacterial IMPDH enzymes are those
from E. coli, Streptococcus pyogenes, Streptococcus suis, Bacillus subtilis,
Borrelia burgdorferi, Halobacterium salinarum and M. tuberculosis
[10,14,24–29]. IMPDH exists as a homotetramer [6,26]. Each
monomer consists of two domains: the larger catalytic core domain
which forms an (a,b)8 barrel and a smaller subdomain containing
two cystathionine b synthase (CBS) domains also called the
bateman domain [6,14]. The subdomain is not required for
activity although still present in all the IMPDHs characterized to
date [30]. In E. coli the subdomain is known to regulate the
distribution of adenine and guanine nucleotide pools [31]. The
larger domain contains an active site loop at the C-terminal end of
the b barrel strands [6,32]. The substrates, IMP and NAD
+ bind
to the active site and, following NADH release, E-XMP* is
hydrolysed [33]. During the enzymatic oxidation of IMP to XMP,
the active site cysteine residue is covalently modified [6,34].
In order to preselect for Mt-GuaB2 inhibitors that show
antibacterial activity, we selected scaffolds based on whole cell
antibacterial data from our previous M. tuberculosis H37Rv screens
of three libraries: the NIH Molecular Libraries Small Molecule
Repository (MLSMR) (NIH Roadmap Initiative) [35], the Life
Chemicals kinase library [36] and an in house Chembridge library
[37]. All compound selections were made from active compounds
and full dose-response data from these screens: 2273 actives
identified from the MLSMR, 1781 from the Chembridge set and
1329 from the kinase library. Only a small number of non-
nucleoside, small molecule IMPDH ligands has been published for
various species. We utilized core scaffolds of these known IMPDH
ligands for searching our TB active sets for potential M. tuberculosis
IMPDH inhibitors [10,14,38–46]. The search resulted in the
identification of five analogues of the known IMPDH inhibitor
scaffold 2-phenoxy-N-phenylpropanamide [38] and these com-
pounds were included in the set of compounds evaluated in this
study.
A focused scaffold-based approach was applied to select further
compounds that also possess structural novelty as potential Mt-
GuaB2 inhibitors. The Cryptosporidium parvum IMPDH crystal
structure contains inosinate and the small molecule c46 co-
crystallized in the active site [40]. We identified a structurally
diverse set of small scaffolds that may be overlaid onto distinct
regions of the c64 ligand as present in the crystal structure, and
our M. tuberculosis H37Rv active sets were searched for hits that
contain these substructures. Twelve such small scaffolds led to the
identification of forty-three compounds among the reported TB
actives, and these are shown in Figure S1. Out of the M. tuberculosis
H37Rv actives identified based on these searches thirty-three
compounds were selected for evaluation against Mt-GuaB2. These
compounds include fifteen hits from the Chembridge library
(Figure S2) and eighteen hits listed in Figure S3 that are available
from Life Chemicals and a single compound from ChemDiv. The
identified inhibitors were tested for in vitro antibacterial activity
against M. tuberculosis and M. smegmatis, cellular cytotoxicity, and in
functional Mt-GuaB2 in vitro assays to determine the inhibition
constants and mechanism of enzyme inhibition. The target of two
of the most potent Mt-GuaB2 inhibitors were identified.
Methods
Ethics Statement
All experimental mouse protocols and details of animal welfare
and steps to ameliorate suffering were approved with written
consent by the Animal Care Use Committee of Colarado State
University (approval numbers ACUC # 04-302A-06 and ACUC
# 06-221A-03), which abides by the USDA Animal Welfare Act
and the Public Health Service Policy on Humane Care and Use of
Laboratory Animals.
Chemicals
IMP and NAD
+ were purchased from Sigma Aldrich (St. Louis,
MO, USA).
Compound libraries
The set of thirty three small molecule compounds selected for
evaluation was purchased from the commercial vendors Chem-
bridge (Chembridge set), Life Chemicals and ChemDiv (Life
Chemicals set) and were used as supplied from the vendors without
further characterization or purification. The stock solutions of the
test compounds were prepared in DMSO and stored at 220uC.
Structures of the Chembridge set of compounds are listed in
Figure S2 and the Life Chemicals set in Figure S3.
Cuvettes
Special reduced volume UV transparent ultra micro plastibrand
disposable cuvettes were obtained from Brand GmBH (Germany).
Cloning, expression and purification of Mt-GuaB2
Mt-GuaB2 was cloned into pET28b, overexpressed in E. coli as
a N-terminal poly histidine fusion and purified using the protocol
previously described [10]. In this study 461L large scale cultures
were grown in terrific broth supplemented with potassium salts
instead of the Luria- Bertani broth.
Mt-GuaB2 activity assay
The Mt-GuaB2 assay was carried out according to the protocol
described previously except that the assay was re-standardized
using a final volume of 200 ml [10]. Mt-GuaB2 activity was
monitored by using a UV spectrophotometer (Jenway) and
measuring the rate of formation of NADH at 340 nm for
5 minutes at 37uC. The reaction mixture (200 ml) contained
50 mM Tris.Cl pH 8.5, 150 mM KCl, 1 mM EDTA, 1 mM
DTT, 1 mM IMP, 2.8 mM NAD
+ and 3 mg of purified enzyme.
The reaction was initiated by addition of substrate, IMP or NAD
+
after preincubation of the other reaction components for 5 min at
37uC. The concentrations of IMP or NAD
+ were varied for Km (app)
determination at saturating concentrations of the other substrate
and the initial rate data were fitted to the Michaelis Menten
equation using Graphpad prism software. For determination of the
Km (app) value for IMP, the concentration of IMP in the reaction
mixture was varied from 0.010–1.5 mM at saturating concentra-
tions of NAD
+ (2.8 mM). A minus IMP control was included.
Initial rate data were also generated using a fixed IMP
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+ concentrations
(0.031–3.0 mM). The slope was determined from the linear
portion of the reaction time course and plotted against IMP or
NAD
+ concentration (mM).
Inhibitor kinetics
The Ki value for NAD
+ was determined at a constant saturating
IMP concentration (1.086 mM, Km IMP 108.6 mM) and three
different concentrations of NAD
+ (0.35, 0.70 and 1.4 mM) in the
presence of increasing concentrations of inhibitor (0.01–1000 mM).
The value of Ki for IMP was determined at fixed saturating
concentration of NAD
+ (2.8 mM, Km NAD
+ 699.4 mM) and
different concentrations of IMP (0.054, 0.108 and 0.217 mM) and
inhibitor (0.01–1000 mM). Mt-GuaB2 was pre-incubated with
varying inhibitor concentrations for five minutes at 37uC prior to
addition of IMP or NAD
+ to start the reaction, and the samples
were assayed for remaining enzyme activity over a five minute
period. The inhibitors were dissolved in 100% DMSO and diluted
to a final concentration of 1% in experimental reactions, i.e. 2 ml
of the inhibitor stock was used in a 200 ml enzyme assay. In control
samples, compounds were replaced with the same volume of neat
DMSO. The initial velocities at various inhibitor concentrations
were determined based on the slope in the linear part of each
reaction containing the inhibitor and the uninhibited reaction. To
determine the inhibition constant (Ki values) the initial rate data
versus substrate concentration at different inhibitor concentrations
were fit using the program Prism version 5.0 (GraphPad San
Diego, CA) to equations for uncompetitive, competitive, or
noncompetitive inhibition. For each inhibitor concentration, the
reciprocal of enzyme reaction velocity versus the reciprocal of the
substrate concentration was plotted in a Lineweaver-Burk plot to
determine the pattern of inhibition.
Drug susceptibility testing of wild type M. smegmatis,
recombinant Mt-GuaB2 cloned in pVV16 and wild type
M. tuberculosis
The susceptibility of M. smegmatis cells overexpressing the Mt-
GuaB2 plasmid or empty pVV16 vector control was determined in
the presence of increasing drug concentrations (compounds
5217501, 6655281 and 7759844) as described previously for the
diphenyl ureas (DPU’s) [10]. Each compound was freshly dissolved
in DMSO at a concentration of 10 mg/ml. The final concentra-
tion of DMSO in the MIC assays was 1%. To determine the
minimum inhibitory concentration (MIC) of wild type M. smegmatis
the cultures were grown to an OD600 of 0.7, serially diluted ten
fold (10
21 to 10
24) and spotted (5 ml) on tryptic soy broth (TSB)
agar plates containing two fold serial dilutions of the compound
(0.25–128 mg/ml) or an untreated control (neat DMSO). The
plates were incubated at 37uC for 3 days. The MIC is defined as
the minimal concentration required to completely inhibit 99% of
mycobacterial growth. All evaluated compounds were previously
screened for activity against M. tuberculosis using a whole cell
microplate Alamar blue assay [35–37].
Determination of bactericidal activity of compounds
against M. smegmatis
M. smegmatis was grown in MB7H9 broth containing 0.2% (v/v)
glycerol, 0.05% Tween 80 and 10% ADC enrichment till early
logarithmic phase (OD600 of 0.8) and the cells were subsequently
diluted to an OD600 of 0.035 (,1610
6 cfu/ml) with MB7H9
broth. Diluted bacterial cultures (3 ml aliquots) were added to
each tube containing the two fold dilutions of compound 5217501
(1.5–48 mg/ml), 6655281 (0.75–100 mg/ml) and 7759844 (0.5–
32 mg/ml) and the control tubes containing neat DMSO and were
incubated with continuous agitation at 180 rpm and 37uC for
24 hours. Post incubation, the cultures (0.1 ml) were serially
diluted ten fold (10
21 to 10
26) with MB7H9 broth and the
bactericidal effect of compounds determined by plating 0.1 ml
volumes of 10
24,1 0
25 and 10
26 dilutions on MB7H10 agar plates
containing 0.5% glycerol and 10% OADC enrichment after
incubation at 37uC for 3 days. The resulting bacterial colonies
were counted. Percent inhibition is defined as number of colonies
in the compound treated tubes divided by the number of colonies
in untreated tubes, times 100%. The experiment was done in
duplicate and the mean and standard error determined. The
minimum bactericidal concentration (MBC) is defined as the
minimal concentration which effectively reduced at least 99% of
the viable counts in the compound treated sample compared with
untreated samples.
Modeling Mt-GuaB2–IMP complex structure
Mt-GuaB2 was modeled based on the human IMPDH type II
crystal structure (PDB code 1NFB), utilizing a previously published
sequence alignment [10]. The sequence identity between Mt-
GuaB2 and the human type II IMPDH template in the modeled
region is 49.51%, well above the ,30% threshold typically
considered acceptable for homology modeling. The initial
homology model was relaxed through restrained energy minimi-
zation using Impact tools from the Protein Preparation Refine-
ment module of the Schrodinger software package. The substrate
IMP was modeled into the active site of Mt-GuaB2, and taken
from the Cryptosporidium parvum IMPDH crystal structure (PDB
code 3KHJ) after superimposing the latter structure onto the Mt-
GuaB2 model. After the initial energy minimization of the
obtained protein–IMP complex, the protein part was replaced
by the structure prior to energy minimization, and the system re-
minimized with restrained energy optimization in Impact
(Schrodinger software). This approach allowed an initial adjust-
ment of IMP prior to relaxing the protein structure together with
IMP. The structure of IMP in the obtained Mt-GuaB2–IMP
model was close to that of the co-crystallized purine riboside
phosphate present in the human type II IMPDH (1NFB) structure;
slight deviations between these two related ligands are limited to
the purine ring, which is covalently linked to the protein in the
human type II IMPDH crystal structure but not in the Mt-GuaB2-
IMP model. Residues that participate in direct interactions with
either ligands in these two complex structures are conserved
between the two except for the conservative replacement of R322
in the human type II IMPDH by K332 in Mt-GuaB2.
In vivo studies
Maximum tolerated dose (MTD) test. Concurrent with
the advanced enzymatic screens, compound 7759844 was selected
for further evaluation in vivo due to its excellent activity against M.
tuberculosis H37Rv and strong inhibition of Mt-GuaB2. Both
toxicity and efficacy in a murine M. tuberculosis model were
undertaken in order to evaluate these scaffolds as further
candidates for antitubercular drug discovery against IMPDH. In
two separate studies, the tolerability of 7759844 was studied in an
acute maximum tolerated dose C57BL/6 mouse model (MTD) to
evaluate toxicity and determine a safe dose in the murine TB
model. Mice were administered a single dose of compound
formulated in 0.5% methyl cellulose at three doses (100, 300, and
500 mg/kg) by gavage followed by observation for seven days.
There were no dose related adverse effects seen through the
highest dose (500 mg/kg). Subsequently, 7759844 was tested for
efficacy in GKO mice.
Mycobacterial GuaB2 Inhibitor Series
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Once an acceptable MTD value was determined, the
compounds were tested for in vivo efficacy in a short term mouse
M. tuberculosis model. This approach uses the interferon-c gene-
disrupted C57BL/6 mice (GKO) in a murine TB aerosol infection
model developed and extensively tested by Lenaerts et al [47].
GKO mice do not mount an adaptive immune response and any
antitubercular efficacy seen can be exclusively attributed to drug
action [48,49]. GKO mice were infected with M. tuberculosis
Erdman strain by a low dose aerosol (LDA) exposure using a MB
aerosol generation device [47]. GKO mice are highly susceptible
to M. tuberculosis infection and the short term mouse model
required only eight days of treatment after fifteen days of infection
[50], allowing the rapid in vivo assessment of candidate drugs for
antitubercular activity. Twelve week old female GKO mice
obtained from Jackson laboratories were used in this study. After
fifteen days of infection, mice were treated by oral gavage with
7759844 for eight consecutive days until the twenty-third day and
sacrificed on the twenty-fourth day. Each group consisted of five
mice. The first group received 300 mg/kg body weight of
7759844, the second group received the positive control isoniazid
at 25 mg/kg body weight and the third group was the untreated
negative control. Compound 7759844 was suspended in 0.5%
methyl cellulose and isoniazid was dissolved in sterile water. At the
end of the experiment the lung and spleen homogenates of
untreated and drug treated mice were cultured and the viable
colonies were counted after four weeks of incubation at 37uC. The
viable counts were converted to logarithms and the mean of
7759844 was compared with the untreated control by one way
analysis of variance (ANOVA) followed by Dunnett’s post-test.
Results
Purification of Mt-GuaB2
Recombinant Mt-GuaB2 was overexpressed in E. coli and the
enzyme purified by a single step HisTrap Ni
2+ chelating Sepharose
affinity chromatography. SDS-PAGE showed a distinct band of
Mt-GuaB2 at an apparent molecular weight of approximately
57 kDa (Figure S4). The fractions of highest purity were retained,
pooled, dialysed, concentrated and used for the activity assays.
Determination of Km (app) for substrates
The assay volume was reduced to 200 ml from 1 ml and the
kinetic constants reassessed as reported [10]. The Mt-GuaB2
activity was examined with variable concentrations of substrate
and a fixed saturating concentration of co-substrate to determine
the kinetic constants. The Km (app) of IMP and NAD
+ were
determined to be 108.6+/211.97 mM and 699.4+/263.70 mM
respectively (Figure S5). The Km (app) of IMP was lower and that of
NAD
+ higher than that reported earlier [10]. Compared to
mammalian IMPDHs, bacterial IMPDH enzymes tend to bind
IMP more effectively and bind NAD
+ with a low affinity [26]. The
pathogenic bacterium S. pyogenes IMPDH has kinetic characteris-
tics similar to other bacterial IMPDH enzymes, its Km value for
NAD
+ is on the ‘high’ end, approximately 1180 mM and its Km for
IMP on the ‘low’ end, 62 mM [29,34].
Screening of the Chembridge and Life Chemicals sets
against purified Mt-GuaB2 and determination of Ki values
A selected set of commercially available compounds from the
Chembridge and the Life Chemicals libraries were evaluated for
their inhibition in the spectrophotometric assay using purified Mt-
GuaB2. Inhibition constants, Ki values, with respect to both
substrates IMP and NAD
+ were determined by assaying various
concentrations of the inhibitor in the presence of three different
concentrations of substrate and a fixed saturating concentration of
the co-substrate. The inhibition data for the fifteen Chembridge
compounds are summarized in Table 1. Almost eleven compounds
in this set were found to inhibit Mt-GuaB2 with Ki values lower
than 100 mM and four hits bolded in Table 1 have low
micromolar inhibition constants. The most potent compounds
5217501 and 7759844 have Ki values in the nanomolar range with
respect to both substrates IMP and NAD
+ and also inhibit M.
tuberculosis and M. smegmatis growth. The analogue 6655281 shows
low micromolar inhibition, substantial anti-mycobacterial activity
against M. tuberculosis and it was the most potent compound in this
series against M. smegmatis growth. All compounds excepting
7577905 yielded an uncompetitive inhibition pattern with respect
to IMP and NAD
+. Figures 1 and 2 illustrated the pattern of
inhibition of the three Chembridge hits with low micromolar Ki. Ki
values were determined from nonlinear regression analysis in
GraphPad prism by fitting data to the equation for uncompetitive
inhibition.
Table 2 listed the activity and inhibition constant data for the
Life Chemicals compound set, consisting of seventeen compounds
from Life Chemicals and one from ChemDiv. Compound F1374-
1083 was the best inhibitor in this set with low micromolar Ki, and
also inhibited M. tuberculosis growth but did not inhibit M. smegmatis
growth even at the highest concentration tested (128 mg/ml). All
except for F1374-0253 were uncompetitive inhibitors of the
enzyme with respect to the substrate NAD
+, and all these
compounds showed uncompetitive inhibition with respect to IMP.
Evaluation of compounds for antimycobacterial activity
The Chembridge and Life Chemicals sets were assessed for in
vitro anti-mycobacterial activity against M. tuberculosis and M.
smegmatis. Only compounds that have shown significant antimy-
cobacterial activity against M. tuberculosis H37Rv in our previous
screens [35–37] were included among compounds selected for the
evaluations shown in Tables 1 and 2. For Chembridge compounds
(Table 1), the M. tuberculosis MIC90’s range from 0.63–10.43 mg/
ml. The most potent compounds included analogues of the 2-
phenoxy-N-phenylpropanamide scaffold [38] such as 7759844,
7756985, 7409994, and the novel structures 7577905, 9008726,
5217501, 7383310 (for structures see Figure S2). The most potent
Chembridge compound against M. smegmatis was 6655281 with a
MIC90 of 0.75 mg/ml. It was structurally similar to reported
IMPDH inhibitor scaffold [38]. Furthermore, two analogues
(7759844 and 7756985) of this known scaffold were effective at
inhibiting M. smegmatis growth. A structurally novel inhibitor,
5217501, was effective against both M. tuberculosis and M. smegmatis,
showing MIC90 values of 4.83 and 12 mg/ml respectively. The
selectivity index (SI) was calculated taking the ratio of the
mammalian cell cytotoxicity (EC50) to the concentration of
compound needed to inhibit bacterial growth by 90%
(SI=EC50/IC90), and the reported selectivity index for 5217501
was greater than 8.76 [37]. The hits with the best reported SI
values in Table 1 were 7759844 and 7756985, SI.23.70 and
.18.66, respectively [37]. These two compounds were also potent
inhibitors of both M. tuberculosis and M. smegmatis.
Of the eighteen hits from the Life Chemicals and ChemDiv
compound set, seven compounds exhibited antimycobacterial
activity against M. smegmatis, four of which possessed
MIC90’s#8 mg/ml (Table 2). M. tuberculosis MIC90’s were less
than 6.88 mg/ml for all compounds (except for one untested
ChemDiv compound, 1499-0691). The structurally novel com-
pound F1374-1083 was the most potent (a low micromolar
inhibitor in the enzyme assay) although it was inactive up to
Mycobacterial GuaB2 Inhibitor Series
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M. tuberculosis growth inhibitor in this set with an MIC90 of
0.41 mg/ml and a high selectivity index (SI .96.85) although it
was also inactive against M. smegmatis.
Effects of three Chembridge compounds on viability of
M. smegmatis
In order to determine whether selected (MIC values #12 mg/
ml) Chembridge compounds (5217501, 6655281 and 7759844)
were bactericidal or bacteriostatic against M. smegmatis, colonies
were enumerated after 24 hours exposure to the compounds at
different concentrations after plating 100 ml of diluted bacterial
suspension on MB7H10 agar plates. For reference, an untreated
control was included and the bactericidal effect of the compounds
was compared between treated and untreated cultures.
All three compounds reduced colony forming units of M.
smegmatis culture in a dose dependent manner when compared to
the untreated control indicating that the compounds were
bactericidal. The kill curves for the three compounds are shown
in Figure 3. The most effective compound against M. smegmatis was
5217501 which showed 99% inhibition of bacterial growth at
12 mg/ml and complete inhibition of growth at higher concentra-
tions. The minimum bactericidal concentration (MBC) values
obtained for compounds 6655281 and 7759844 were 40 mg/ml
and 32 mg/ml, respectively.
Investigation of the mode of action of selected
Chembridge compounds
Three selected Chembridge compounds (5217501, 6655281
and 7759844) inhibited Mt-GuaB2; their Ki values were in the low
micromolar range. For the mode of action (MOA) studies, the
MIC’s of the Mt-GuaB2 overexpressing strain in pVV16 was
determined and compared with the MIC’s of the vector alone
control (pVV16) and wild type M. smegmatis. The Mt-GuaB2
overexpressing strain showed a four fold increase in MIC for
compound 6655281 and a 6 fold increase in MIC for compound
7759844 which indicated that these two compounds inhibited M.
smegmatis growth due to the inhibition of Mt-GuaB2 (Figure 4).
Hence, the target of these two inhibitors appeared to be Mt-
GuaB2. The possibility of other additional unknown targets for
these inhibitors cannot be ruled out and might exist. In the case of
compound 5217501, the MIC’s obtained for the Mt-GuaB2
overexpressing strain was similar to those of the pVV16 vector
control and wild type M. smegmatis which suggested that compound
5217501 did not primarily target Mt-GuaB2 (Figure 4) in the
bacterium.
Docking lead inhibitor into Mt-GuaB2 and selectivity
considerations against human IMPDH type II
Compound 7759844 was docked into the Mt-GuaB2–IMP
complex structure using the InducedFit docking protocol from the
Schrodinger software package that treated residues within 5 A ˚ of
docked ligand conformers as flexible. Two possible docked
orientations were predicted for this ligand, one showed excellent
consistency with the limited SAR data available for this lead
scaffold, as listed in Table 3. Therefore, we considered this mode
as our working model of 7759844 binding to Mt-GuaB2, for
further validation. Our working ligand binding pose of 7759844 is
shown in Figure 5 and as a 2-D illustration in Figure 6. Figures 5
and 6 illustrated the docked pose of the (S)-enantiomer. The
terminal 4-iodophenyl group of the ligand forms an optimal
aromatic stacking interaction with IMP and interacts favorably
with the positively charged guanidinium moiety of R108.
Interestingly, the same interaction could not form in case of the
human type II IMPDH where this Arg was replaced by H93.
Although the imidazole ring of a His could form favorable
interactions with the phenyl ring, its shorter side chain would place
the imidazole beyond an optimal distance. Any change or
deviation in the position of the phenyl ring from that of the
optimal for aromatic stacking with IMP would likely result in a loss
Table 1. aKi (mM) values of Chembridge compounds against IMP and NAD
+, in vitro activity of Chembridge compounds against M.
tuberculosis H37Rv and M. smegmatis and selectivity index (SI).
ChemBridge I.d. IMP Ki (mM) IMP aKi (mM) NAD Ki (mM) NAD aKi (mM)
M. tb MIC90
(mg/ml) SI
M. smeg MIC90
(mg/ml)
5217501 0.548 (UC) 0.523 (UC) 4.83 .8.76 12
6655281 16.7 (UC) 13.9 (UC) 3.45 3.66 0.75
7240597 101.6 (UC) 94.1 (UC) 10.43 NA 40
7383310 36.9 (UC) 95.8 (UC) 5.50 .2.73 20
7407367 142.3 (UC) 141.3 (UC) 7.45 .2.01 .28
7409994 6.46 (UC) 3.36 (UC) 3.27 .4.59 .128
7577905 243.6 (NC) 151.4 (C) 2.35 .6.37 48
7610600 34.6 (UC) 29.2 (UC) 1.65 .9.11 .96
7622922 136.5 (UC) 804.8 (UC) 1.84 .8.14 .128
7741101 42.9 (UC) 72.1 (UC) 5.47 .7.31 .128
7741703 24.7 (UC) 24.8 (UC) 3.29 .4.56 48
7756985 96.6 (UC) 207.4 (UC) 0.80 .18.66 4
7759844 0.603 (UC) 0.233 (UC) 0.63 .23.70 8
7913222 126.0 (UC) 92.3 (UC) 6.27 .2.39 64
9008726 31.0 (UC) 44.0 (UC) 4.26 .15 NA
SI defined as
Vero EC50 mg=ml ðÞ
MIC90 mg=ml ðÞ
i.e. the ratio of vero cell cytotoxicity to the anti-TB activity.
Note: (UC) stands for Uncompetitive inhibition, (NC) Noncompetitive, (C) Competitive, (NA) Not available and (SI) Selectivity index.
doi:10.1371/journal.pone.0033886.t001
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data available (Table 3). The dramatic reduction of activity upon
introducing an ortho-Me on this ring (and replacing I with Cl) may
be due to the effect of perturbing the phenyl position from the
optimal stacking interactions with IMP. In the docked structure,
the distance between the phenyl’s 2-carbon and the closest
backbone atom (of M424) was only 3.7 A ˚, and therefore, a methyl
substituent could not be accommodated at this position without
perturbing the phenyl ring and its stacking interaction with IMP.
Rotating the ring in the docked structure would cause the ortho-Me
to clash with IMP. The amide carbonyl of 7759844 in the docked
pose was hydrogen bonded with the backbone of A285 while the
Ala side chain was positioned at 3.9 A ˚ distance from the terminal
phenyl ring. In the human IMPDH sequence A285 corresponded
to S276 and, considering the analogous pose bound to the human
IMPDH, Ser replacing Ala would be less favorable at such close
Figure 1. Mechanism of inhibition graphs of Chembridge compounds 5217501 and 6655281 against substrates IMP and NAD
+. The
recombinant Mt-GuaB2 enzyme from E. coli was assayed as described in Materials and Methods in the absence of inhibitor and increasing
concentrations of compounds 5217501 and 6655281. IMP and inhibitor were used at varying concentrations (Top panel), the reaction was started by
addition of a fixed saturating concentration of NAD
+ and the OD measured at 340 nm. In the bottom panel a variable concentration of NAD
+ and
inhibitor was used and a fixed saturating IMP concentration to initiate the reaction. The velocity data were fitted in Graphpad prism by a nonlinear
regression method. Compounds were assayed in duplicate and the data represent the mean +/2 standard error of two independent experiments.
The 1/V versus 1/[Sub] plot at the inset (top) of each graph was generated to indicate the pattern of inhibition.
doi:10.1371/journal.pone.0033886.g001
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against M. tuberculosis and M. smegmatis and selectivity index (SI) values.
Life Chemicals I.d. IMP aKi (mM) NAD Ki (mM) NAD aKi (mM)
M. tb MIC90
(mg/ml) SI
M. smeg MIC90
(mg/ml)
F1374-0033 60.9 (UC) 45.0 (UC) 1.75 7.89 8
F1374-0205 35.3 (UC) 100.0 (UC) 5.59 3.43 .128
F1374-0253 11.2 (UC) 434.6 (NC) 5.30 .7.55 .128
F1374-0873 35.5 (UC) 47.3 (UC) 5.84 .6.85 .128
F1374-0885 19.0 (UC) 28.2 (UC) 0.72 6.55 2
F1374-0978 28.3 (UC) 31.8 (UC) 2.98
a 4.6
a .128
F1374-1083 4.86 (UC) 6.13 (UC) 4.81 .8.31 .128
F1499-0691 404.2 (UC) 273.9 (UC) NA NA 4
F1685-0077 229.3 (UC) 275.6 (UC) 6.88 .5.81 .128
F2517-0198 19.1 (UC) 64.9 (UC) 2.68 3.84 .128
F2518-0183 57.1 (UC) 73.5 (UC) 1.76
a 17
a .128
F2518-0274 765.4 (UC) 895.3 (UC) 5.50 5.11 20
F2518-0386 22.6 (UC) 55.1 (UC) 0.41
a .96.85
a .128
F2518-0401 501.9 (UC) 591.0 (UC) 1.18 12.51 16
F2518-0413 36.4 (UC) 52.7 (UC) 1.23 6.67 .128
F2518-0418 328.7 (UC) 478.2 (UC) 2.24 8.20 32
F2518-0484 35.5 (UC) 71.3 (UC) 6.70 .5.97 3
F2536-1573 79.0 (UC) 55.0 (UC) 1.02 6.68 .128
Compound 1499-0691 from ChemDiv is also included in this set.
Note: (UC) stands for Uncompetitive inhibition, (NC) Noncompetitive, (NA) Not available and (SI) Selectivity index.
aM.tb MIC90 (mg/ml) and SI values cited from Reynolds et al., 2011.
doi:10.1371/journal.pone.0033886.t002
Figure 2. Mechanism of inhibition of Chembridge compound 7759844 against both substrates IMP and NAD
+. The purified Mt-GuaB2
enzyme was incubated at 37uC for five minutes with substrate in the absence and presence of different concentrations of compound 7759844 and
the reaction started by addition of NAD
+ or IMP. The initial velocity data were plotted against three different IMP (left panel) or NAD
+ concentrations
(right panel) and varying inhibitor concentrations. The data represent the mean +/2 standard error of duplicate experiments. The 1/V versus 1/[Sub]
plot at the inset (top) of each graph only depicted the type of inhibition.
doi:10.1371/journal.pone.0033886.g002
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favorable non-polar and hydrogen bonding interactions with
T343 would favor the S enantiomer as opposed to the R
enantiomer while prediction showed consistency with the
inhibition data previously reported for the enantiomers of a close
analog [46]. In the environment surrounding the ligand’s 4-OMe-
phenyl group, V345 and H286 corresponded to E335, Q277,
respectively, in the human sequence. Although these residues have
no direct contacts with the docked 7759844 inhibitor, they might
be explored by other analogs or other compounds for improve-
ment of selectivity against human IMPDH. Note that the
evaluated sample of 7759844 was a racemic mixture, and both
enantiomers were used for docking.
Animal studies
The efficacy of compound 7759844 was tested in an in vivo short
term mouse infection (GKO) model. Prior to efficacy testing the
compound was examined for toxicity in normal C57BL/6 mice
and the compound 7759844 was well tolerated with no acute
adverse effects observed at the highest single dose of 500 mg/kg.
Efficacy of the compound was evaluated by administering daily
doses of 7759844 at 300 mg/kg body weight for eight consecutive
days via oral gavage to GKO mice beginning on day fifteen of
infection. Even at a dose under the MTD for C57BL/6 mice,
7759844 caused distress in infected interferon-c gene-disrupted
C57BL/6 mice (GKO), and three animals were sacrificed after
eight days of dosing. The compound was inactive and did not
reduce the bacterial load in lungs, but it showed slight activity in
the spleen, and reduced the bacterial load by 0.84 log10 protection
units when compared to the untreated controls (Table S1 and
Figure S6). Isoniazid reduced the number of colony forming units
by 2.7 log10 protection units in lungs and 4.0 log10 protection units
in the spleen versus the drug free control (Table S1 and Figure S6).
Discussion
The potential of IMPDH for immunosuppressive, cancer and
antiviral chemotherapy has been previously explored. Recently,
Mt-GuaB2 has gained attention as a promising anti-mycobacterial
target, associated with a number of distinct inhibitor scaffolds
[10,24]. The applicability of available bacterial IMPDH inhibitors
may be limited by toxicity issues as there is an important human
homolog, and lead optimization must focus on selectivity as well as
potency. In the search for new lead compounds as potential Mt-
GuaB2 inhibitors, we employed a designed scaffold-based
approach utilizing the IMPDH crystal structure with c64 co-
crystallized in the active site (PDB code 3KHJ). M. tuberculosis
H37Rv active sets from our previous screens [35–37] were
searched based on a set of designed scaffolds listed in Figure S1 as
well as a known IMPDH scaffold [38]. Of the identified M.
tuberculosis actives, we evaluated thirty-three compounds for their
potential to inhibit Mt-GuaB2 functional activity and for their
inhibitory potency against M. smegmatis.
In the present study, the assay was adapted to a 200 ml volume,
conditions were optimized by varying concentrations of the
Figure 3. Effect of three Chembridge compounds on the viability of M. smegmatis. Early log phase M. smegmatis culture was adjusted to
1610
6 cfu/ml with MB7H9 broth and the culture incubated in absence (DMSO) and presence of various concentrations of inhibitor (5217501,
6655281 and 7759844) at 37uC for 24 hours. A 100 ml aliquot of 24 hour culture was serially diluted, plated on MB7H10 agar plates and incubated at
37uC for 3 days. The number of bacterial colonies in compound treated tube divided by the number of colonies in untreated tube, times 100% gave
the % inhibition values which were plotted against varying inhibitor concentrations. The mean +/2 standard error values of the experiment done in
duplicate were plotted.
doi:10.1371/journal.pone.0033886.g003
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+ and the enzyme, and the Km
(app) were determined for IMP and NAD
+. The optimized assay
yielded a reaction that proceeded linearly over a 5 min period.
Next, we studied the inhibition of Mt-GuaB2 by a series of
commercially available compounds, primarily from the Chem-
bridge and Life Chemicals libraries. When compared to the
DPU’s, these compounds show an improvement in enzyme
inhibitory activity, yielding low micromolar inhibitors. The Ki
values were obtained for all inhibitors with respect to both
substrates IMP and NAD
+, and the patterns of inhibition were
inferred from the graphs. Among the Chembridge compounds,
four (5217501, 6655281, 7409994 and 7759844) exhibited low
micromolar affinity Ki values. Out of the Life Chemicals
compound set, F1374-1083 showed a low micromolar inhibition
constant. All inhibitors from the Chembridge compound set
(except for 7577905) showed an uncompetitive pattern of
inhibition against both substrates. Uncompetitive inhibition has
been observed previously versus both IMP and NAD
+, in the case
of compounds having a strong preference for the E-XMP*
complex [14]. The observation of an uncompetitive pattern of
inhibition also depended on assay conditions [51]. In the case of
uncompetitive inhibition, both the substrates bind to the enzyme
before the inhibitor binds. The uncompetitive inhibitors have an
advantage as drugs since inhibition increased due to accumulation
of substrates [52].
Except for compound F1374-0253, all compounds from the Life
Chemicals set showed uncompetitive inhibition with respect to
both IMP and NAD
+. Well known uncompetitive inhibitors are
MPA, an NAD
+ mimic, SAD (which is an analog of tiazofurin
metabolite TAD) and VX-497 [6,17]. Uncompetitive inhibitors
bind to the cofactor NAD
+ binding portion of the active site [25].
MPA does not structurally resemble either the substrates or
products of the IMPDH reaction. Like MPA, most uncompetitive
inhibitors trap E-XMP* [51]. Life Chemicals compound F1374-
0253 shows uncompetitive inhibition versus IMP and noncompet-
itive inhibition versus NAD
+. Such a pattern of inhibition is
exemplified by thiazole-adenine-dinucleotide (TAD) [51].
The minimum bactericidal concentration and mode of inhibition
has been evaluated for three promising Chembridge compounds,
5217501, 6655281 and 7759844 that potently inhibit Mt-GuaB2
activity and show substantial inhibition of M. smegmatis growth in vitro.
Compound 7759844 has the 2-phenoxy-N-phenylpropanamide core
structure of a known IMP dehydrogenase inhibitor scaffold [38] and
Figure 4. Determination of MIC (mg/ml) of three Chembridge compounds against M. smegmatis overexpressing Mt-GuaB2, M.
smegmatis pVV16 and M. smegmatis mc
2 155 to ascertain the mode of action. M. smegmatis mc
2 155 (left plate), M. smegmatis pVV16
(middle plate) and Mt-GuaB2 overexpression construct in pVV16 (right plate) were grown to mid log phase and serial dilutions of cultures (10
21 to
10
24) were spotted on TSB plates in the absence and presence of different concentrations of compounds 6655281 and 7759844. The plates were
incubated at 37uC for 3 days. The minimal concentration of the inhibitor which completely inhibited 99% of M. smegmatis growth was considered as
MIC. The MIC results of compound 5217501 are shown in the table below.
doi:10.1371/journal.pone.0033886.g004
Table 3. Analogs of lead scaffold from Figure S2 docked into
Mt-GuaB2 model.
ChemBridge I.d. IMP aKi (mM) M. tb MIC90 (mg/ml)
7759844 0.603 0.633
7756985 96.64 0.804
7240597 101.6 10.43
7407367 142.3 7.447
7409994 6.458 3.266
doi:10.1371/journal.pone.0033886.t003
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6655281 also shares some structural similarities to the latter scaffold,
while the inhibitor 5217501 structure is novel. IMPDH is a cellular
target of compounds 6655281 and 7759844, although additional
cellular targets cannot be ruled out. If the pathway is blocked by an
IMPDH inhibitor DNA and RNA synthesis will be inhibited resulting
in death of the organism [53]. The molecular target of compound
5217501 remains unknown. In this study we have shown that Mt-
GuaB2 is not the likely target for the antimycobacterial activity of this
compound.
Figure 5. Mt-GuaB2–IMP model structure with docked lead 7759844. Close-up view of the docked lead 7759844 and IMP at the substrate
binding region of the Mt-GuaB2 model. Amino acids mapping the ligand/substrate binding site are shown. Atoms are colored by type (oxygens red,
nitrogens blue, sulfur yellow, polar hydrogens white). Carbon atoms of the enzyme, IMP and lead 7759844 are colored green, purple and light brown,
respectively. The inset shows the 2-D structures of the ligand and IMP.
doi:10.1371/journal.pone.0033886.g005
Figure 6. 2-D representation of predicted interactions between lead 7759844 and the Mt-GuaB2–IMP structure. This 2-D
representation corresponds to the Mt-GuaB2-IMP model and docked ligand shown in Figure 5, illustrating residues that interact with lead 7759844.
Polar interactions are indicated with dashed lines.
doi:10.1371/journal.pone.0033886.g006
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cell M. smegmatis while showing potent inhibitory activity against M.
tuberculosis cultures. A possible explanation may be that M. smegmatis
is intrinsically resistant to many antibiotics due to the low number of
porins which contributes to low permeability through its cell wall
[54,55]. M. smegmatis is known to be naturally resistant to
compounds of certain classes and shows a resistance to the frontline
drugs rifampicin and isoniazid [56]. The lipid bilayer is abnormally
thick and shows unusually low fluidity since the trans double bonds
present in the a-mycolates decrease fluidity and permeability in M.
smegmatis [54,57]. Other than the cell wall permeation barrier, there
are additional resistance mechanisms which contribute to intrinsic
drug resistance of M. smegmatis potentially including multidrug efflux
pumps and enzymatic inactivation of drugs [57,58]. In this study we
identified eight hits that potently inhibit M. smegmatis growth. Four
compounds from each of the Chembridge and Life Chemicals
compound set showed good M. smegmatis MIC90 values ranging
from 0.75 mg/ml to 12 mg/ml.
Compound 7759844 has a good selectivity index (SI.23.70),
potently inhibited M. tuberculosis growth, and inhibits Mt-GuaB2 at
nanomolar levels. Hence, the lead compound 7759844 was further
evaluated in vivo in a mouse model of TB infection based on
reported selection criteria [59]. Although the compound was not
toxic at 500 mg/kg in a single acute dose MTD determination in
normal C57BL/6 mice, the sample was not well tolerated in a
more chronic daily dosing regimen of 300 mg/kg for eight days in
M. tuberculosis infected interferon-c gene disrupted C57BL/6
(GKO) mice. Beyond these toxicity issues, compound 7759844
was not able to significantly impact disease progression in the
GKO efficacy model. Currently, it is not clear what the cause of
the observed toxicity might be, although IMPDH is an important
enzyme in mammals. Furthermore, in vivo metabolic hydrolysis of
the arylamide of 7759844 could potentially lead to formation of
substituted anilines that are known to undergo metabolic oxidation
leading to toxic/genotoxic species. At this point, this highly active
class of Mt-GuaB2 inhibitor exemplified by 7759844 remains an
excellent lead scaffold for further optimization and development of
more active and selective compounds as candidates for new
antitubercular drugs. Other classes of inhibitors identified in these
studies may also prove fruitful for further drug discovery and
development against M. tuberculosis IMPDH.
Supporting Information
Figure S1 Designed fragments used for searching TB
active sets. The number of TB actives containing each fragment
is shown in parenthesis.
(TIF)
Figure S2 Chemical structures of the Chembridge
compound set evaluated in this study.
(TIF)
Figure S3 Chemical structures of the LifeChemical
compound set. Included also is compound 1499-0691 which
is from ChemDiv.
(TIF)
Figure S4 SDS-PAGE analysis of purified Mt-GuaB2
fractions. An aliquot of a series of gradient elutions of increasing
imidazole concentrations (150, 200, 300, 400 and 500 mM) were
loaded in lanes 1 to 5 of the 12% SDS-PAGE gel after purification
through a Ni
2+ chelate affinity chromatography column. Lane 6
contains the protein molecular weight marker and the numbers
towards the right are the molecular masses in kDa. Mt-GuaB2 was
visualized after Coomassie blue staining. The arrow in left
indicates the purified Mt-GuaB2.
(TIF)
Figure S5 Determination of Km (app) of substrates IMP
(A) and NAD
+ (B). Michaelis Menten plot of recombinant Mt-
GuaB2 enzyme activity was plotted as a function of varying
concentrations of IMP (A) and varying concentrations of NAD
+
(B). To determine the Km (app) values of IMP and NAD
+ the initial
velocity data were fitted to Michaelis Menten equation using
nonlinear regression function. The substrate concentration curves
were carried out in triplicates. The values represent the mean +/2
standard error of three independent experiments.
(TIF)
Figure S6 Efficacy of Chembridge compound 7759844 in
the GKO animal model. GKO mice were infected with M.
tuberculosis Erdman strain as described in Materials and Methods.
On the fifteenth day of infection, 7759844 (300 mg/kg) and the
positive control isoniazid (25 mg/kg) were administered by oral
gavage for eight days. Infected untreated mice served as negative
control. The mice were sacrificed on day twenty four, the lung and
spleen were aspectically removed and homogenates prepared. The
number of viable organisms in lungs and spleen were determined
by serial ten fold dilutions of homogenates and subsequent plating
of dilutions in 7H10 agar plates and incubation at 37uC for 4
weeks. The cfu counts were converted to logarithms and the mean
cfu of 7759844 treated mice were compared with untreated mice
by one way analysis of variance followed by Dunnett’s post test.
(TIF)
Table S1 In vivo activity of Isoniazid and Chembridge
compound 7759844 in the GKO mouse model.
(DOC)
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